3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
38
Melanoma
15
Neoplasm Metastasis
12
Squamous Cell Carcinoma of Head and Neck
11
Lung Neoplasms
11
Skin Neoplasms
10
Neoplasms
9
Ovarian Neoplasms
8
Recurrence
7
Colorectal Neoplasms
7
Carcinoma, Renal Cell
7
Urinary Bladder Neoplasms
6
Head and Neck Neoplasms
6
Carcinoma, Basal Cell
6
Breast Neoplasms
6
Adenocarcinoma
6
Uterine Cervical Neoplasms
5
Triple Negative Breast Neoplasms
5
Colonic Neoplasms
5
Carcinoma, Squamous Cell
5
Carcinoma, Merkel Cell
5
Carcinoma
5
Prostatic Neoplasms
4
Pancreatic Neoplasms
4
Mouth Neoplasms
4
Glioblastoma
4
Fallopian Tube Neoplasms
4
Stomach Neoplasms
3
Sarcoma
3
Mycosis Fungoides
3
Interventions
pembrolizumab
2
enzalutamide
2
abiraterone
2
Immune Checkpoint Inhibitors
2
Cytochrome P-450 Enzyme System
2
durvalumab
1
dostarlimab
1
cemiplimab
1
blinatumomab
1
atezolizumab
1
Surgical Instruments
1
Hydroxyurea
1
Etoposide
1
Etanercept
1
Carboplatin
1
Androgen Receptor Antagonists
1
AMG 757
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Bites and Stings
×
cemiplimab
×
1 year
×
Clear all
NCT06022029
2025-12-24
ON-5001
OncoNano Medicine, Inc.
Phase 1
Recruiting
168 enrolled